P1-076: EBUS TBNA compared to mediastinoscopy  by Krasnik, Mark et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS580
The combined procedure was diagnostic in 67% of the patients(52/67)
Conclusions: EBUS TBNA and EUS FNA is both effective and non 
invasive methods to obtain a diagnose in patients with lesions of un-
known origin in the lungs and mediastinum
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Objective: The aim of the present study was to compare the results 
from EBUS-TBNA with standard medi-astinoscopy in the evaluation of 
mediastinal lymph nodes in patients with lung cancer or undiag-nosed 
solid lesion in the mediastinum 
Methods: The combination of EBUS TBNA and mediastinoscopy was 
prospective performed in 66 patients during the same general anaesthe-
sia.
Results: A total of 66 patients (29 females and 37 males mean age 60 
years) underwent EBUS TBNA and Mediastinoscopy combined. 
I 61 patients (93%) EBUS TBNA the result was consistent with the 
ﬁnal diagnose and the medi-astnoscopy was correct in 53 patients 
(80%). In one patient both mediastinoscopy and EBUS TBNA was 
false negative.
The ﬁnal diagnose for the patients were 55 cancers, 1 tuberculosis. 1 
lymphoma, 3 sarcoidosis and 6 inﬂamations.
NPV and PPV for the two methods will be discussed.
Conclusions: EBUS-TBNA is an accurate, safe and minimally invasive 
diagnostic technique for the staging of mediastinal lymph nodes. It’s 
routine use for this purpose instead of mediastinoscopy should be 
considered 
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Background: Early and precise response evaluation is of great value 
in patients (pts) with advanced/metastatic NSCLC in order not only to 
reduce toxicity and additional cost by ineffective and unnecessary toxic 
treatment but also to get a chance to receive other possible effective 
treatments earlier. We conducted a prospective study to evaluate 18-
ﬂuorodeoxyglucose positron emission tomography-computed tomogra-
phy (PET-CT) for early prediction of response and survival.
Methods: Between May 2004 and November 2005, 31 pts [gender, 
23M, 8F; stage, 2IIIB, 29IV, histology, 6 squamous cell ca, 22 adenoca, 
3 NOS; age, median 57 (30-73 yr)] with pathologically proven NSCLC 
stage IIIB/IV participated into this study. PET response or metabolic 
response was measured prospectively according to recommendations of 
the EORTC PET study group after one cycle of treatment. Radiologic 
response or best overall response was determined according to WHO 
response criteria every 3 cycles or when clinically indicated.
Results: Pts underwent systemic treatment with gemcitabine/vinorel-
bine (15), gemcitabine/cisplatin (1) gemcitabine/vinorelbine/cisplatin 
(1), irinotecan/cisplatin (9) or geﬁtinib (5). Out of 31 pts, there were 
12 PRs (38.7%), 5 SDs and 14 PDs. Out of 13 progressive metabolic 
diseases (PMD), there were 9 PRs, 3 SDs and 1 PR, while all of 7 
partial metabolic responses (PMR) were conﬁrmed to reach PR. When 
increased pleural effusion identiﬁed on PET-CT was deﬁned as PMD, 
there were 17 PMDs, of which there were 13 PDs, 2 SDs and 2 PR. 
As radiologic response was signiﬁcantly correlated with time-to-pro-
gression and survival time (p<0.001 and p=0.015, respectively), early 
metabolic response was signiﬁcantly correlated with them (p<.0.001 
and p=0.031, respectively).
Conclusions: FDG-PET-CT can predict early he best response to 
treatment. Therefore, the early use of FDG-PET-CT can reduce side 
effects and costs of ineffective therapy in non-responding patients and 
may early predict response to new therapeutic agents. However, the 
patients showing equivocal metabolic response will be reassessed by 
subsequent response evaluation. Our study needs to be validated in a 
larger series.
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Background: Lung cancer is rarely found in young patients, especially 
in those younger than 40 years of age. It has been suggested that the 
clinical features, pathologic ﬁndings, and prognosis in young patients 
with lung cancer differ from those in elderly patients with lung cancer. 
The aim of this study was to describe the CT features of lung cancer in 
patients under the age of 40.
Methods: We retrospectively reviewed demographic ﬁndings, histol-
ogy and staging of lung cancer under the age of 40 years among 6,876 
patients who were diagnosed to have primary lung cancer at our hos-
pital during the period from 2001 to 2006. CT ﬁndings were retrospec-
tively assessed in terms of the location (peripheral or central), shape 
(mass or consolidation) and size of primary tumor, presence of pleural 
or pericardial effusion and pleural nodules and pattern of lung metas-
tasis [micronodular (< 5mm), macronodular (≥ 5mm), or lymphangitic 
metastasis].
Results: Primary lung cancer was diagnosed in 132 patients (1.9%). 
They were 70 men and 62 women with mean age of 34 years (range 13 
- 39 years). One hundred patients (76%) had adenocarcinoma; 11 (8%), 
non small cell carcinoma-not otherwise speciﬁed; 9 (7%), squamous 
cell carcinoma; 8 (6%), small cell carcinoma; 2 (2%), adenosquamous 
cell carcinoma; and one each (1%), sarcomatoid carcinoma and muco-
epidermoid carcinoma. At the time of diagnosis 9 (7%) had stage I, 1 
(1%) stage II, 30 (23%) stage III, and 92 (70%) stage IV. 
In 117 patients, 50 lesions were located in central and 67 were in 
peripheral. Fifteen lung cancers were consolidation type. The longest 
